AC Immune SA ACIU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACIU is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.45
- Day Range
- $2.42–2.69
- 52-Week Range
- $1.78–5.14
- Bid/Ask
- $2.18 / $2.85
- Market Cap
- $239.34 Mil
- Volume/Avg
- 250,553 / 172,154
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 161
- Website
- https://www.acimmune.com
Comparables
Valuation
|
Metric
|
ACIU
|
MLTX
|
VECT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.27 | 5.31 | 4.95 |
Price/Sales | 12.60 | — | 27.19 |
Price/Cash Flow | — | — | — |
Price/Earnings
ACIU
MLTX
VECT
Financial Strength
|
Metric
|
ACIU
|
MLTX
|
VECT
|
|---|---|---|---|
Quick Ratio | 8.74 | 51.38 | 9.01 |
Current Ratio | 9.22 | 51.59 | 9.14 |
Interest Coverage | −313.02 | — | −41.28 |
Quick Ratio
ACIU
MLTX
VECT
Profitability
|
Metric
|
ACIU
|
MLTX
|
VECT
|
|---|---|---|---|
Return on Assets (Normalized) | −30.01% | −11.20% | −37.23% |
Return on Equity (Normalized) | −33.60% | −12.51% | −44.82% |
Return on Invested Capital (Normalized) | −33.51% | −11.49% | −42.88% |
Return on Assets
ACIU
MLTX
VECT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yjxfbdzqv | Ypt | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zngjvdfd | Jbvzhf | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ntjrxgf | Ndxmwy | $98.9 Bil | |
MRNA
| Moderna Inc | Dnvjgyvzm | Myh | $39.7 Bil | |
ARGX
| argenx SE ADR | Gzbxnvk | Rfnq | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Gwkpnty | Fwz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ztkfdhw | Gpgqs | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xvfqqfhd | Qrqnzgr | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zhzkmnkkxc | Fnfdzk | $12.3 Bil | |
INCY
| Incyte Corp | Tqjrccqbh | Splnx | $11.8 Bil |